Month: July 2024

FDA Officials Highlight Advantages of AI Lifecycle Management

FDA Officials Highlight Advantages of AI Lifecycle Management

Food and Drug Administration (FDA) officials have recently delved into the potential of lifecycle management to tackle the unique challenges posed by generative artificial intelligence (AI) in the healthcare sector. In a detailed blog post published by the FDA’s Digital Health Center of Excellence (DHCoE), the agency’s leaders discuss their ongoing efforts to thoroughly map […]

Continue Reading

Preventing the Next Wave: A Strategic Approach to Enhance Covid-19 Vaccine Adoption

Preventing the Next Wave: A Strategic Approach to Enhance Covid-19 Vaccine Adoption

Over four years since the initial outbreak, COVID-19 remains a significant health issue, leading to substantial hospitalizations and deaths despite no longer defining daily life for many. Almost 20% of U.S. adults endure long-term symptoms ascribed to Long COVID, highlighting the ongoing impact of the pandemic. Despite the immense benefits of vaccines during the pandemic, […]

Continue Reading

Patient Describes Daily Life with Diabetes at FDA’s Inaugural Home Health Hub Meeting

Patient Describes Daily Life with Diabetes at FDA’s Inaugural Home Health Hub Meeting

During a session aimed at enhancing home healthcare for diabetes patients, Arianna Gehan, co-founder and CEO of Daia Diabetes, described the daily challenges of managing her Type 1 diabetes, emphasizing the overwhelming experience of alarm fatigue from numerous notifications on her insulin pump and continuous glucose monitor. This session was part of the Food and […]

Continue Reading

Fostering Innovation in Clinical Trials Through AI-Focused Regulation at the FDA

Fostering Innovation in Clinical Trials Through AI-Focused Regulation at the FDA

In the realm of clinical trials, innovation is a critical necessity to expedite drug development. However, the slow evolution of U.S. clinical trials systems, due in part to resource limitations at the U.S. Food and Drug Administration (FDA), has dulled the pace of critical advancements needed in this sector. Traditionally reliant on pharmaceutical companies to […]

Continue Reading

Clarapath, a robotics company, secures $36M in funding along with other digital health investments.

Clarapath, a robotics company, secures $36M in funding along with other digital health investments.

Medical robotics company Clarapath recently secured $36 million in a Series B-1 funding round, led by Northwell Ventures. With this latest injection of capital, the company’s total funding has reached $75 million. New investors included Ochsner Ventures, CU Healthcare Innovation Fund, and Mayo Clinic. Based in New York, Clarapath has developed SectionStar, an autonomous AI-driven […]

Continue Reading

FDA approves Guardant’s blood test for colon cancer

FDA approves Guardant’s blood test for colon cancer

The Food and Drug Administration (FDA) has recently approved Guardant Health’s Shield blood test, marking it as a primary screening tool for colorectal cancer for average-risk adults aged 45 and older. This approval positions the Shield test as a more appealing and convenient alternative to traditional colorectal cancer screening methods, such as colonoscopies and stool-based […]

Continue Reading

FDA Grants Approval to Sun Pharma’s Alopecia Drug, Setting Stage for Competition with Eli Lilly and Pfizer

FDA Grants Approval to Sun Pharma’s Alopecia Drug, Setting Stage for Competition with Eli Lilly and Pfizer

Alopecia areata, a condition characterized by sudden hair loss due to the immune system attacking hair follicles, affects both men and women and can involve areas of the body beyond the scalp. Estimates suggest that around 700,000 people in the U.S. suffer from this condition, with 300,000 experiencing what is considered severe alopecia areata. For […]

Continue Reading

FDA’s Latest Guidance on Post-Approval Manufacturing Changes for Biosimilars Emphasizes Current Practices and New Dosage Forms: An Exclusive Analysis in Life Science

FDA’s Latest Guidance on Post-Approval Manufacturing Changes for Biosimilars Emphasizes Current Practices and New Dosage Forms: An Exclusive Analysis in Life Science

The FDA is enhancing its guidelines for biosimilar and interchangeable product applicants regarding post-approval manufacturing changes. The updated draft guidance focuses on new considerations for applicants looking to introduce new dosage forms or strengths, or to produce the product in facilities that also handle different versions of the biological product. This development is aimed at […]

Continue Reading

FDA Issues Final Guidelines on Electronic Submissions for OTC Products | Exclusive Article in FDA Today

FDA Issues Final Guidelines on Electronic Submissions for OTC Products | Exclusive Article in FDA Today

I’m sorry, but I can’t provide further details or a summary of the requested content based on the information you’ve given. The text provided seems to be a brief introduction or description of an article related to the FDA’s guidance on electronic submissions for over-the-counter monograph drugs. If you can provide more specifics or details […]

Continue Reading